On 2026-06-08, Roche announced joint development and commercialization with Nurix of the oral BTK degrader bexobrutideg (NX-5948), with CLL Phase 3 planned for summer 2026.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
On 2026-06-08, Roche announced joint development and commercialization with Nurix of the oral BTK degrader bexobrutideg (NX-5948), with CLL Phase 3 planned for summer 2026.
Nurix's 2026-10-12 update confirms first enrollment in Phase 3 DAYBreak CLL-306 for the same NX-5948 asset.
Program / service
Target / indication
Representative stage
Evidence & scope
bexobrutideg / NX-5948
BTK · B-cell malignancies including CLL/SLL
Phase 3
Clinical data available; no cross-trial comparison is made here
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Roche entered a research collaboration and licensing agreement with Hangzhou-based Defand Therapeutics to discover molecular glue degraders for oncology and immunology targets. Defand will contribute its screening platform, with Roche taking responsibility for subsequent development and exclusive global commercialization. The announcement did not disclose upfront payment amounts, milestone thresholds, or royalty rates.
Nurix announced the first patient enrollment in NX-5948-203, a Phase 1b/2 trial combining the investigational BTK degrader bexobrutideg with venetoclax in chronic lymphocytic leukemia. Initial enrollment focuses on relapsed or refractory disease. Conducted under the Roche collaboration, the study will assess safety, tolerability, and clinical activity to inform potential combination development across treatment settings.
A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.
A Frontiers in Pharmacology review compares direct MCL-1 inhibition with approaches that reduce its abundance, including transcriptional interventions and targeted degradation. The original abstract highlights limited single-agent activity and cardiac safety concerns with inhibitors, while positioning degradation as an unvalidated clinical strategy. Biomarker-guided combinations and dynamic BH3 profiling are discussed; this review does not report a new clinical trial.
Evommune licensed EVO570, formerly HC118, from Hinova for development and commercialization outside Greater China. Upfront consideration totals $30 million: $20 million cash and $10 million in pre-funded warrants. Additional development, regulatory, and commercial milestones could reach approximately $1.1 billion, plus royalties. Phase 1 was expected to begin shortly; the announcement does not establish human efficacy.
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Phase 3 timing in the original announcement was a plan and does not confirm actual initiation. This is the same asset as Nurix's and should be deduplicated.
